Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Crowley, Stephanie J. | - |
dc.contributor.author | Bruck, Patrick T. | - |
dc.contributor.author | Bhuiyan, Md Aladdin | - |
dc.contributor.author | Mitchell-Gears, Amelia | - |
dc.contributor.author | Walsh, Michael J. | - |
dc.contributor.author | Zhangxu, Kevin | - |
dc.contributor.author | Ali, Lestat R. | - |
dc.contributor.author | Jeong, Hee-Jin | - |
dc.contributor.author | Ingram, Jessica R. | - |
dc.contributor.author | Knipe, David M. | - |
dc.contributor.author | Ploegh, Hidde L. | - |
dc.contributor.author | Dougan, Michael | - |
dc.contributor.author | Dougan, Stephanie K. | - |
dc.date.available | 2020-07-10T02:30:49Z | - |
dc.date.created | 2020-07-06 | - |
dc.date.issued | 2020-02-05 | - |
dc.identifier.issn | 2046-2441 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hongik/handle/2020.sw.hongik/585 | - |
dc.description.abstract | Cancer-specific mutations can lead to peptides of unique sequence presented on MHC class I to CD8 T cells. These neoantigens can be potent tumour-rejection antigens, appear to be the driving force behind responsiveness to anti-CTLA-4 and anti-PD1/L1-based therapies and have been used to develop personalized vaccines. The platform for delivering neoantigen-based vaccines has varied, and further optimization of both platform and adjuvant will be necessary to achieve scalable vaccine products that are therapeutically effective at a reasonable cost. Here, we developed a platform for testing potential CD8 T cell tumour vaccine candidates. We used a high-affinity alpaca-derived VHH against MHC class II to deliver peptides to professional antigen-presenting cells. We show in vitro and in vivo that peptides derived from the model antigen ovalbumin are better able to activate naive ovalbumin-specific CD8 T cells when conjugated to an MHC class II-specific VHH when compared with an irrelevant control VHH. We then used the VHH-peptide platform to evaluate a panel of candidate neoantigens in vivo in a mouse model of pancreatic cancer. None of the candidate neoantigens tested led to protection from tumour challenge; however, we were able to show vaccine-induced CD8 T cell responses to a melanoma self-antigen that was augmented by combination therapy with the synthetic cytokine mimetic Neo2/15. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ROYAL SOC | - |
dc.subject | CERVICAL-CANCER PATIENTS | - |
dc.subject | CTLA-4 BLOCKADE | - |
dc.subject | DENDRITIC CELLS | - |
dc.subject | INTERLEUKIN-2 | - |
dc.subject | IMMUNOTHERAPY | - |
dc.subject | VACCINES | - |
dc.subject | INDUCTION | - |
dc.subject | IL-2 | - |
dc.subject | E6 | - |
dc.title | Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jeong, Hee-Jin | - |
dc.identifier.doi | 10.1098/rsob.190235 | - |
dc.identifier.scopusid | 2-s2.0-85078989417 | - |
dc.identifier.wosid | 000511414900002 | - |
dc.identifier.bibliographicCitation | OPEN BIOLOGY, v.10, no.2 | - |
dc.relation.isPartOf | OPEN BIOLOGY | - |
dc.citation.title | OPEN BIOLOGY | - |
dc.citation.volume | 10 | - |
dc.citation.number | 2 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.subject.keywordPlus | CERVICAL-CANCER PATIENTS | - |
dc.subject.keywordPlus | CTLA-4 BLOCKADE | - |
dc.subject.keywordPlus | DENDRITIC CELLS | - |
dc.subject.keywordPlus | INTERLEUKIN-2 | - |
dc.subject.keywordPlus | IMMUNOTHERAPY | - |
dc.subject.keywordPlus | VACCINES | - |
dc.subject.keywordPlus | INDUCTION | - |
dc.subject.keywordPlus | IL-2 | - |
dc.subject.keywordPlus | E6 | - |
dc.subject.keywordAuthor | VHH | - |
dc.subject.keywordAuthor | cancer vaccines | - |
dc.subject.keywordAuthor | cytokines | - |
dc.subject.keywordAuthor | cancer immunology | - |
dc.subject.keywordAuthor | neoantigens | - |
dc.subject.keywordAuthor | alpaca nanobodies | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
94, Wausan-ro, Mapo-gu, Seoul, 04066, Korea02-320-1314
COPYRIGHT 2020 HONGIK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.